Loading...
Cardiotoxicity with adjuvant trastuzumab use in breast cancer: A single institution’s experience
BACKGROUND: Trastuzumab use in Her-2-neu positive breast cancer patients is the current standard of care. Trastuzumab is known to result in cardiotoxicity. The toxicity seems to be dose-dependent, and serial cardiology assessment with echocardiography is advised. In spite of this, patients do develo...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3727509/ https://ncbi.nlm.nih.gov/pubmed/23960606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsha.2010.04.009 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|